Ganesh Sahathevan

 by Ganesh Sahathevan                                               Despite official and unofficial booster mandates, that have come over and above vaccine mandates from their major customers, the governments of primarily developed countries with plenty of capacity to pay for their products, the share price and market capitalisation of the main vaccine producers have all collapsed. Vaccitech which formulated  the AstraZeneca vaccine is now trading at almost half its IPO price of USD 17, which it only got to briefly after the IPO. BoiNTech which formulated and  produces the Pfizer-BioNTech vaccine has seen its share price collapse to approximately USD 1500, after getting to a high of just above USD 400, in under 12 months, despite a slew of good news.  Moderna and Novavax have also seen their share price and market capitalisation fall off a cliff. Any company that experiences share price and market capitalisation collapse such as the above will come under scrutiny from its customers (an

 by Ganesh Sahathevan  “Vaccines wane,” Tony Blakely, a University of Melbourne epidemiologis said. “The increase in NSW is entirely expected even before you consider Omicron. Omicron didn’t start this kick-up, but it’s going to fan it, and numbers will go up even faster.” In the recent vaccine mandate case of Kassam v Hazzard Beech-Jones J of the NSW Supreme Court held that NSW Minister for Health Brad Hazard had every right to be an "advocate for vaccination" for the Minister can be expected to be a "policy advocate". Since that decision was handed down in October 2021 93.6% of NSW's 16 and over population have been double or fully vaccinated. Herd immunity should have been achieved, but it has not. COVID infection in NSW has reached a record of over 20,000 per day, a record that is more than 15 times the previous high. The COVID vaccines have clearly failed in what they were meant to do, for they are meant to prevent infection. A BioNTech/Pfizer funded stud